These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23118327)

  • 1. Impact of hydrolysis-mediated clearance on the pharmacokinetics of novel anaplastic lymphoma kinase inhibitors.
    Teffera Y; Berry LM; Brake RL; Lewis RT; Saffran DC; Moore E; Liu J; Zhao Z
    Drug Metab Dispos; 2013 Jan; 41(1):238-47. PubMed ID: 23118327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism and pharmacokinetics of a novel Src kinase inhibitor TG100435 ([7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) and its active N-oxide metabolite TG100855 ([7-(2,6-dichloro-phenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-{4-[2-(1-oxy-pyrrolidin-1-yl)-ethoxy]-phenyl}-amine).
    Hu SX; Soll R; Yee S; Lohse DL; Kousba A; Zeng B; Yu X; McPherson A; Renick J; Cao J; Tabak A; Hood J; Doukas J; Noronha G; Martin M
    Drug Metab Dispos; 2007 Jun; 35(6):929-36. PubMed ID: 17371799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and metabolism of a RAS farnesyl transferase inhibitor in rats and dogs: in vitro-in vivo correlation.
    Singh R; Chen IW; Jin L; Silva MV; Arison BH; Lin JH; Wong BK
    Drug Metab Dispos; 2001 Dec; 29(12):1578-87. PubMed ID: 11717177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737): identification of an unusual N-acetylglucosamine conjugate in the cynomolgus monkey.
    Johnson BM; Kamath AV; Leet JE; Liu X; Bhide RS; Tejwani RW; Zhang Y; Qian L; Wei DD; Lombardo LJ; Shu YZ
    Drug Metab Dispos; 2008 Dec; 36(12):2475-83. PubMed ID: 18787055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of ML3403 ({4-[5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-Pyridinylimidazole-type p38 mitogen-activated protein kinase inhibitor.
    Kammerer B; Scheible H; Albrecht W; Gleiter CH; Laufer S
    Drug Metab Dispos; 2007 Jun; 35(6):875-83. PubMed ID: 17344341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor.
    Liu L; Halladay JS; Shin Y; Wong S; Coraggio M; La H; Baumgardner M; Le H; Gopaul S; Boggs J; Kuebler P; Davis JC; Liao XC; Lubach JW; Deese A; Sowell CG; Currie KS; Young WB; Khojasteh SC; Hop CE; Wong H
    Drug Metab Dispos; 2011 Oct; 39(10):1840-9. PubMed ID: 21742900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An inhibitory metabolite leads to dose- and time-dependent pharmacokinetics of (R)-N-{1-[3-(4-ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-ethyl}-N-pyridin-3-yl-methyl-2-(4-trifluoromethoxy-phenyl)-acetamide (AMG 487) in human subjects after multiple dosing.
    Tonn GR; Wong SG; Wong SC; Johnson MG; Ma J; Cho R; Floren LC; Kersey K; Berry K; Marcus AP; Wang X; Van Lengerich B; Medina JC; Pearson PG; Wong BK
    Drug Metab Dispos; 2009 Mar; 37(3):502-13. PubMed ID: 19088267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model.
    Yamazaki S; Skaptason J; Romero D; Vekich S; Jones HM; Tan W; Wilner KD; Koudriakova T
    Drug Metab Dispos; 2011 Mar; 39(3):383-93. PubMed ID: 21098644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioactivation of isothiazoles: minimizing the risk of potential toxicity in drug discovery.
    Teffera Y; Choquette D; Liu J; Colletti AE; Hollis LS; Lin MH; Zhao Z
    Chem Res Toxicol; 2010 Nov; 23(11):1743-52. PubMed ID: 20825217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
    Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
    J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species.
    Kumar V; Schuck EL; Pelletier RD; Farah N; Condon KB; Ye M; Rowbottom C; King BM; Zhang ZY; Saxton PL; Wong YN
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):229-37. PubMed ID: 21698359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor.
    Basavapathruni A; Olhava EJ; Daigle SR; Therkelsen CA; Jin L; Boriack-Sjodin PA; Allain CJ; Klaus CR; Raimondi A; Scott MP; Dovletoglou A; Richon VM; Pollock RM; Copeland RA; Moyer MP; Chesworth R; Pearson PG; Waters NJ
    Biopharm Drug Dispos; 2014 May; 35(4):237-52. PubMed ID: 24415392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
    Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
    J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models.
    Yamazaki S; Vicini P; Shen Z; Zou HY; Lee J; Li Q; Christensen JG; Smith BJ; Shetty B
    J Pharmacol Exp Ther; 2012 Mar; 340(3):549-57. PubMed ID: 22129595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer.
    Lewis RT; Bode CM; Choquette DM; Potashman M; Romero K; Stellwagen JC; Teffera Y; Moore E; Whittington DA; Chen H; Epstein LF; Emkey R; Andrews PS; Yu VL; Saffran DC; Xu M; Drew A; Merkel P; Szilvassy S; Brake RL
    J Med Chem; 2012 Jul; 55(14):6523-40. PubMed ID: 22734674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and tissue distribution of 3-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl)methyl)benzamide; a novel ALK5 inhibitor and a potential anti-fibrosis drug.
    Kim YW; Kim YK; Lee JY; Chang KT; Lee HJ; Kim DK; Sheen YY
    Xenobiotica; 2008 Mar; 38(3):325-39. PubMed ID: 18274960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials.
    Marsilje TH; Pei W; Chen B; Lu W; Uno T; Jin Y; Jiang T; Kim S; Li N; Warmuth M; Sarkisova Y; Sun F; Steffy A; Pferdekamper AC; Li AG; Joseph SB; Kim Y; Liu B; Tuntland T; Cui X; Gray NS; Steensma R; Wan Y; Jiang J; Chopiuk G; Li J; Gordon WP; Richmond W; Johnson K; Chang J; Groessl T; He YQ; Phimister A; Aycinena A; Lee CC; Bursulaya B; Karanewsky DS; Seidel HM; Harris JL; Michellys PY
    J Med Chem; 2013 Jul; 56(14):5675-90. PubMed ID: 23742252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of the carboxylesterase inhibitor bis-para-nitrophenylphosphate (BNPP) in the plasma unbound fraction determination for a hydrolytically unstable amide derivative and agonist of the TGR5 receptor.
    Eng H; Niosi M; McDonald TS; Wolford A; Chen Y; Simila ST; Bauman JN; Warmus J; Kalgutkar AS
    Xenobiotica; 2010 Jun; 40(6):369-80. PubMed ID: 20297923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions.
    Choo EF; Belvin M; Boggs J; Deng Y; Hoeflich KP; Ly J; Merchant M; Orr C; Plise E; Robarge K; Martini JF; Kassees R; Aoyama RG; Ramaiya A; Johnston SH
    Drug Metab Dispos; 2012 May; 40(5):919-27. PubMed ID: 22315332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.